Related Experiment Videos
Analysis of the CYP2C19 polymorphism in a North-eastern Thai population
Wichittra Tassaneeyakul1, Arporn Tawalee, Wongwiwat Tassaneeyakul
1Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Thailand. wichit-t@md.kku.ac.th
Pharmacogenetics
|April 3, 2002
Summary
Genetic variations in CYP2C19 enzyme affect drug metabolism. This study found lower poor metabolizer phenotypes and specific allele frequencies in Thai individuals compared to other Asian populations.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Biochemistry
Background:
- CYP2C19 is a key enzyme in drug metabolism, exhibiting significant genetic variability across ethnic groups.
- Poor metabolizer (PM) phenotypes for CYP2C19 vary globally, impacting drug efficacy and safety.
- Understanding ethnic variations in CYP2C19 is crucial for personalized medicine.
Purpose of the Study:
- To investigate the CYP2C19 phenotype and genotype distribution in a North-eastern Thai population.
- To compare these findings with other Oriental and Caucasian populations.
- To identify potential novel genetic variations affecting CYP2C19 function.
Main Methods:
- Phenotyping using the omeprazole hydroxylation index (HI).
- Genotyping via polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
- Analysis of 107 North-eastern Thai subjects.
Main Results:
- The CYP2C19 phenotype distribution was bimodal, with 6.54% identified as poor metabolizers (PM).
- Allele frequencies for CYP2C19*1, CYP2C19*2, and CYP2C19*3 were 0.71, 0.27, and 0.02, respectively.
- The prevalence of PM phenotype and CYP2C19*3 allele was lower in Thais than in other Oriental groups.
Conclusions:
- Thai individuals exhibit distinct CYP2C19 genetic profiles compared to other Asian populations.
- The observed frequencies suggest potentially different drug responses in this population.
- Further investigation is needed for a non-concordant phenotype-genotype case, possibly indicating a novel allele.